EQT to acquire QIAGEN for €10.8 billion in cash deal
QIAGEN (QGEN) accepted a €10.8B all-cash takeover offer from EQT Private Equity at €46.50 per share, a 40.3% premium over its July 8, 2026 closing price. The deal, subject to regulatory approvals, is expected to close in mid-2027. QIAGEN's boards unanimously approved the transaction, which will delist its shares from the Frankfurt and NYSE exchanges post-closing.
How this was made
The 30-second read
Why it matters
The deal creates a clear catalyst for QIAGEN shareholders and may influence pricing of comparable biotech stocks.
Market read
A major European biotech acquisition that will likely move QIAGEN stock sharply and affect sector sentiment.
What to watch
Regulatory approvals and potential antitrust scrutiny could delay or derail the transaction.
Background
The article reports the first public disclosure of EQT's cash offer for QIAGEN, detailing price, premium, financing, and post‑closing delistings.
Ticker impact
EQT Private Equity announced an all‑cash €46.50 per share takeover offer for QIAGEN, a 40.3% premium, representing a €10.8 billion deal.
upward as the market prices in the takeover premium
First‑report of a large‑scale cash acquisition; premium is substantial and will be reflected in the target's price.
Market effects
Consolidation in the life‑science tools and diagnostics sector may spur M&A activity.
European biotech valuations could be re‑priced following the deal.
Large‑cap M&A adds to overall market activity and may affect related biotech indices.
Counterpoint
Acquirer EQT may face integration risk and financing costs, potentially weighing on its broader portfolio.
Key entities
- AcquirerEQT Private Equity
Private‑equity firm leading the €10.8 billion cash acquisition.
- TargetQIAGEN N.V.
Life‑science tools and diagnostics company being acquired.
